Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 12 sources cited
Key Takeaways
- The FDA-approved maximum dose of Ozempic is 2 mg per week, for type 2 diabetes only.
- For weight loss, the same molecule (semaglutide) is FDA-approved as Wegovy at a maximum dose of 2.4 mg per week.
- Some clinicians prescribe Ozempic off-label for weight loss at 2 mg weekly. Going higher than 2 mg with Ozempic is not FDA-approved and carries safety concerns.
- The STEP 1 trial showed an average 14.9% weight loss at 2.4 mg (Wegovy dose) over 68 weeks (Wilding et al., NEJM 2021).
- Higher doses don't linearly produce more weight loss. The dose-response curve flattens above 2.4 mg, and side effects increase.
Direct answer (40-60 words)
The FDA-approved maximum dose of Ozempic is 2 mg per week, indicated for type 2 diabetes. For weight loss, the same drug (semaglutide) is approved as Wegovy at a maximum dose of 2.4 mg per week. Off-label use of Ozempic for weight loss typically caps at the 2 mg pen.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The 30-second answer
- The Ozempic dose ladder
- The Wegovy dose ladder (semaglutide for weight loss)
- Why Ozempic and Wegovy have different max doses
- How much weight people lose at each dose
- Off-label use of Ozempic for weight loss
- Going higher than the FDA max: what we know
- Side effects at the maximum dose
- When to stay below the max
- Switching from Ozempic to Wegovy
- FAQ
- Sources
- Footer disclaimers
- Article and FAQ schema
The 30-second answer
If you're asking about Ozempic itself, the maximum FDA-approved dose is 2 mg once weekly. That's the highest dose in Ozempic's prescribing information, approved for type 2 diabetes management.
If your underlying question is "what's the maximum dose of semaglutide for weight loss," the answer is 2.4 mg weekly. That's the FDA-approved dose for Wegovy, the same molecule rebranded for chronic weight management. The Ozempic pens don't deliver 2.4 mg, so a patient who wants the full weight-loss dose of semaglutide is usually switched from Ozempic to Wegovy.
A small note that confuses people: Ozempic delivery devices include 0.25, 0.5, 1, 2, 4, and 8 mg pens, but those higher numbers refer to the pen's total contents and per-injection delivery for diabetes titration, not new approved doses for weight loss.
The Ozempic dose ladder
Ozempic is FDA-approved for adults with type 2 diabetes. The titration schedule from the prescribing information:
| Weeks | Dose | Notes |
|---|---|---|
| 1-4 | 0.25 mg | Starter dose; not for glycemic effect |
| 5-8 | 0.5 mg | First maintenance dose |
| 9+ | 1 mg | Second maintenance option |
| 9+ (later approval) | 2 mg | Maximum FDA-approved dose |
The 2 mg dose was added to the Ozempic label in March 2022 (FDA, 2022) based on the SUSTAIN FORTE trial, which showed additional A1c reduction at 2 mg vs 1 mg in patients with type 2 diabetes who needed more glycemic control (Frias et al., Lancet 2021).
What Ozempic pens deliver:
- 0.25/0.5 mg pen: delivers either 0.25 mg or 0.5 mg per dose
- 1 mg pen: delivers 1 mg per dose
- 2 mg pen: delivers 2 mg per dose
- 4 mg / 8 mg pens: total contents for multi-dose use; per-injection dose is still capped at the maximum approved dose
So if you're using Ozempic, the highest single dose you'll ever inject under FDA-approved use is 2 mg per week.
The Wegovy dose ladder (semaglutide for weight loss)
Wegovy is also semaglutide, made by the same manufacturer (Novo Nordisk), but approved for weight loss. The FDA-approved titration:
| Weeks | Dose |
|---|---|
| 1-4 | 0.25 mg |
| 5-8 | 0.5 mg |
| 9-12 | 1 mg |
| 13-16 | 1.7 mg |
| 17+ | 2.4 mg (maximum) |
The 2.4 mg dose is the target maintenance dose for chronic weight management. It's higher than Ozempic's 2 mg cap, and it includes the intermediate 1.7 mg step that Ozempic doesn't have.
The pens are also different. Wegovy comes as a single-dose, single-use auto-injector at each strength. Ozempic comes as a multi-dose pen.
[Internal link to /articles/medications/wegovy-dosing-schedule/]
Why Ozempic and Wegovy have different max doses
The same molecule is approved at different maximum doses for two different indications. Here's why:
Different clinical trial programs. Ozempic's diabetes trials (SUSTAIN program) tested doses up to 2 mg. Wegovy's weight-loss trials (STEP program) tested up to 2.4 mg. The FDA approves what was studied, at the doses that were studied.
Different efficacy goals. For diabetes, the goal is A1c reduction. The dose-response for A1c plateaus around 1-2 mg. Pushing higher gives diminishing glycemic returns. For weight loss, the goal is body weight reduction. The dose-response for weight is steeper, and 2.4 mg gave meaningfully more weight loss than 1 mg in trials.
Different side-effect tradeoffs. Higher doses produce more nausea, diarrhea, and other GI side effects. For diabetes patients, the cost-benefit of pushing past 2 mg wasn't favorable. For weight-loss patients motivated by significant weight reduction, the additional GI side effects of 2.4 mg were considered acceptable.
Different insurance and labeling reasons. Selling the same molecule at different doses under two brand names allows different pricing, different patient populations, and different insurance benefit structures.
The bottom line: 2.4 mg is the right dose for weight loss because that's what was tested and what's labeled. The 2 mg Ozempic dose is right for diabetes for the same reason.
How much weight people lose at each dose
The STEP 1 trial (Wilding et al., NEJM 2021) randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks.
Average weight loss at 68 weeks:
| Group | Average weight loss |
|---|---|
| Placebo | 2.4% |
| Semaglutide 2.4 mg | 14.9% |
For a 200-pound person, that's a 30-pound average weight loss on the 2.4 mg dose over about 16 months.
For Ozempic doses below 2.4 mg used in diabetes trials, weight loss was lower:
| Dose | Average weight loss in diabetes trials |
|---|---|
| 0.5 mg | ~4% over 30 weeks |
| 1 mg | ~6% over 30 weeks |
| 2 mg | ~6.9% over 40 weeks |
Diabetes trial weight loss is generally lower than weight-loss trial numbers for two reasons: diabetes blunts GLP-1 weight-loss response, and diabetes trial protocols don't include intensive lifestyle counseling.
A patient using Ozempic 2 mg off-label for weight loss should expect weight loss closer to the 6.9% number than to the 14.9% Wegovy number, simply because the dose is lower.
Off-label use of Ozempic for weight loss
Many U.S. patients use Ozempic off-label for weight loss. This typically happens for two reasons:
- Insurance coverage. Some commercial plans cover Ozempic (for diabetes) but deny Wegovy (for weight loss). When the cheaper option is the diabetes drug, that's what gets prescribed.
- Supply. During the 2022-2024 GLP-1 shortage, Wegovy was harder to obtain than Ozempic, and prescribers used what was available.
Off-label prescribing is legal. A clinician can prescribe any FDA-approved medication for any indication they believe is medically appropriate. But it does come with caveats:
- Insurance may deny coverage if the diagnosis on the claim doesn't match the FDA-approved indication.
- The dose tested for weight loss (2.4 mg) isn't available in Ozempic pens.
- The clinician is responsible for the off-label decision and should document medical necessity.
A common off-label pattern: titrate Ozempic 0.25 → 0.5 → 1 → 2 mg over 16 weeks and stay at 2 mg. This delivers the same effect as the Wegovy 1.7-2 mg range but doesn't reach 2.4 mg.
Going higher than the FDA max: what we know
The FDA has not approved semaglutide above 2.4 mg per week for any indication. Some published research has explored higher doses:
- A 2021 phase 2 trial tested semaglutide doses up to 2.4 mg per week and found that's where the weight-loss benefit started flattening (O'Neil et al., Lancet 2018).
- Newer molecules in development (CagriSema, monlunabant, retatrutide) target higher weight loss through different mechanisms, not by pushing semaglutide above 2.4 mg.
- A 2023 study by Knop and colleagues tested oral semaglutide at 50 mg per day (vs the 2.4 mg weekly subcutaneous), with similar weight loss to Wegovy 2.4 mg. Different formulation, same effective exposure (Knop et al., Lancet 2023).
The practical conclusion: pushing semaglutide above 2.4 mg weekly does not appear to produce meaningfully more weight loss, and side effects increase. Patients who plateau on 2.4 mg and want more weight loss are typically transitioned to tirzepatide (Zepbound) rather than dosed up on semaglutide.
[Internal link to /articles/comparison/semaglutide-vs-tirzepatide-for-weight-loss/]
Side effects at the maximum dose
Side effects on semaglutide are dose-related. Going from 1 mg to 2 mg or 2.4 mg increases:
| Side effect | Frequency at 1 mg | At 2-2.4 mg |
|---|---|---|
| Nausea | ~15-20% | ~30-44% |
| Diarrhea | ~9-11% | ~20-25% |
| Constipation | ~5-8% | ~15-24% |
| Vomiting | ~5% | ~12-15% |
| Abdominal pain | ~5-8% | ~15-20% |
| Decreased appetite | Common | Very common |
Most GI side effects concentrate in the first 4-8 weeks after each dose increase. Slow titration, smaller meals, lower-fat foods, and adequate hydration all reduce GI complaints.
Less common but serious at any dose:
- Pancreatitis (rare)
- Gallbladder disease (more likely with rapid weight loss)
- Diabetic retinopathy progression (in patients with pre-existing retinopathy and diabetes)
- Acute kidney injury (usually triggered by dehydration from severe vomiting/diarrhea)
- Thyroid C-cell tumor warning (boxed warning; no confirmed human cases linked to semaglutide)
If you're escalating the dose and experiencing severe nausea or vomiting, slow down. Hold the current dose for an extra 4 weeks before going up. The titration schedule is a guideline, not a deadline.
When to stay below the max
There are good reasons not to push to the maximum dose. The right dose is the lowest one that achieves your goals with side effects you can tolerate.
Stay below 2.4 mg if:
- You're losing 1-2 lbs per week steadily on a lower dose
- Your appetite is well controlled at the current dose
- You've reached your weight goal (transition to maintenance dosing)
- You're tolerating the current dose well and don't need more
- Side effects are limiting your quality of life
- You're on multiple other medications and want to minimize drug load
Consider going to the max if:
- Weight loss has plateaued at 3+ months on the current dose
- Appetite is creeping back at the current dose
- You're far from your goal and tolerating the current dose well
- Your prescriber agrees the additional benefit is worth the additional side-effect risk
For some patients, the maintenance dose long-term is 1 mg or 1.7 mg, not 2.4 mg. The "right" dose is patient-specific and shouldn't be a race to the top.
Switching from Ozempic to Wegovy
If you're on Ozempic 2 mg for weight loss and your prescriber wants to push you to 2.4 mg, you'll need to switch to Wegovy. The transition is straightforward:
- Last Ozempic dose. Take your scheduled Ozempic 2 mg as usual.
- Wait one week. Your normal weekly dose interval.
- Start Wegovy 1.7 mg. Most prescribers go to 1.7 mg first to bridge the dose gap, even though that's a step down from 2 mg. The reason is that Ozempic and Wegovy pens deliver semaglutide in slightly different formulations and starting at 2.4 mg can spike side effects.
- Stay at 1.7 mg for 4 weeks.
- Step up to 2.4 mg. Continue weekly.
Some prescribers go directly from Ozempic 2 mg to Wegovy 2.4 mg without the 1.7 mg step, especially if the patient has been on 2 mg for several months and tolerated it well. The decision is patient-specific.
Insurance can complicate the switch. Wegovy may require its own prior authorization separate from Ozempic. Get the paperwork started before you run out of Ozempic to avoid a gap.
[Internal link to /articles/medications/switching-ozempic-to-wegovy/]
FAQ
What is the highest dose of Ozempic for weight loss? The FDA-approved maximum for Ozempic is 2 mg weekly, indicated for type 2 diabetes. For weight loss, the equivalent semaglutide product is Wegovy, which goes up to 2.4 mg weekly. Going higher than 2 mg with Ozempic is off-label.
Is 2 mg of Ozempic enough for weight loss? For some patients, yes. Average weight loss on 2 mg in diabetes trials was about 6.9%, less than the 14.9% on Wegovy 2.4 mg. If you're losing weight steadily on 2 mg and tolerating the dose, staying there is reasonable.
Can I take 4 mg of Ozempic? The 4 mg pen exists, but it's a multi-dose pen designed to deliver smaller doses (typically 1 mg or 2 mg per injection). The FDA hasn't approved a 4 mg single dose. Injecting 4 mg in one shot is off-label and carries higher side-effect risk.
What's the difference between Ozempic 2 mg and Wegovy 2.4 mg? Same active drug (semaglutide). The 2.4 mg dose was studied specifically for weight loss in the STEP trial program. The 2 mg dose was studied for diabetes in the SUSTAIN program. Pen design and labeling differ.
Why isn't Ozempic available at 2.4 mg? Ozempic is FDA-approved for type 2 diabetes, where the studied dose range tops out at 2 mg. The 2.4 mg dose is the FDA-approved weight-loss dose under the Wegovy brand. Same molecule, different label, different maximum dose.
Will higher doses of Ozempic give me more weight loss? Up to a point. Going from 0.5 to 1 to 2 mg generally produces more weight loss at each step. Beyond 2.4 mg, the dose-response flattens. Pushing higher doesn't reliably produce more loss but does increase side effects.
How long should I stay at the maximum dose? For most patients on weight-loss therapy, the maintenance dose is meant to be long-term. Stopping the medication usually results in regain of most lost weight within 12 months (Wilding et al., Diabetes Obes Metab 2022).
What happens if I take too much Ozempic? Severe nausea, vomiting, dehydration, and hypoglycemia (especially with diabetes medications) are the main risks of dose excess. Call your prescriber or poison control if you've taken substantially more than your prescribed dose. Most cases resolve with supportive care.
Should I increase to the maximum dose if I'm not losing weight? First evaluate why. Adherence to diet and activity, sleep, stress, other medications, and dose timing all affect weight loss. If you're plateaued for 2-3 months on a stable dose with consistent lifestyle, increasing the dose is reasonable. Discuss with your prescriber.
Can I split a Wegovy 2.4 mg dose in half to make it cheaper? No. Wegovy comes in single-dose pre-filled auto-injectors that aren't designed for partial dosing. Even with a vial-and-syringe alternative, dose splitting changes the pharmacokinetics and isn't recommended.
Is 2.4 mg of compounded semaglutide the same as Wegovy 2.4 mg? The dose is mathematically the same. The drug is not necessarily identical. Compounded semaglutide is prepared by a state-licensed compounding pharmacy and isn't FDA-approved. Sterility, potency, and excipient profiles vary by pharmacy. They are not interchangeable products.
What's the maximum dose of tirzepatide compared to semaglutide? Tirzepatide (Zepbound, Mounjaro) maxes at 15 mg weekly. Semaglutide (Wegovy) maxes at 2.4 mg weekly. The numerical doses aren't directly comparable because they're different molecules with different potencies.
Sources
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564.
- Frias JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg vs 1.0 mg in adults with type 2 diabetes (SUSTAIN FORTE). Lancet. 2021;398(10295):29-40.
- O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity. Lancet. 2018;392(10148):637-649.
- Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1). Lancet. 2023;402(10403):705-719.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- Aronne LJ, Frias JP, Friedrichsen M, et al. Tirzepatide vs semaglutide once weekly in adults with overweight or obesity (SURMOUNT-5). N Engl J Med. 2025;392(15):1387-1397.
- U.S. Food and Drug Administration. Ozempic (semaglutide injection) prescribing information. Initial approval 2017, 2 mg dose added 2022, updated 2024.
- U.S. Food and Drug Administration. Wegovy (semaglutide injection) prescribing information. Initial approval June 2021, updated 2024.
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844.
- American Diabetes Association. Standards of Care in Diabetes 2026: pharmacologic approaches to glycemic treatment.
- Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →